| Literature DB >> 31606870 |
Arnold G Vulto1,2.
Abstract
Fifteen years of experience with biosimilar evaluation in Europe and advancement in the science behind biological medicines, provides a timely moment to open up debate as to whether the requirements for biosimilar approval could be further tailored. Further optimizing of data requirements to truly decisional information will allow to continuously deliver on the promise of biosimilars, providing benefits for patients and society.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31606870 DOI： 10.1007/s40259-019-00388-9
Source DB: PubMed Journal: BioDrugs ISSN： 1173-8804 Impact factor: 5.807